A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumours
The purpose of this study is to evaluate the safety, tolerability pharmacokinetics,
pharmacodynamics, immunogenicity and preliminary anti-tumour activity of BMS-986156 when
administered alone and in combination with nivolumab in subjects with advanced solid tumours.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society